Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
11C-methylphenidate is a radiolabeled analog of methylphenidate in which a carbon-11 (11C) isotope is incorporated for use as a positron emission tomography (PET) imaging agent. It acts as a central nervous system stimulant and is primarily used as a radiotracer to measure dopamine transporter (DAT) availability and distribution in the brain. The mechanism of action is blockade of DAT, allowing for the assessment of dopaminergic neurotransmission via PET. This compound is primarily used in research settings to study brain neurochemistry in conditions such as ADHD, Parkinson’s disease, and other neuropsychiatric disorders, rather than for direct therapeutic purposes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 11C-methylphenidate.